Integra LifeSciences (IART) Tops Q4 EPS by 1c, Revenues Miss; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Outlook Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. FDX
10. BLZE

Go back to Integra LifeSciences (IART) Tops Q4 EPS by 1c, Revenues Miss; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Outlook Below Consensus

Integra LifeSciences Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Guidance

February 19, 2020 6:00 AM EST

PRINCETON, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2019 and issued its financial guidance for 2020, consistent with the preliminary results and guidance provided on January 14, 2020.

Highlights:

Fourth Quarter 2019 Reported revenue increased 3.1% to $395.1 million and organic sales... More